| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2792 |
| Trial ID | NCT05052528 |
| Disease | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | Rituximab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Mehrdad Abedi, MD |
| Other ID(s) | UCDCC#299|NCI-2021-07396|UCDCC#299|P30CA093373 |
| Cohort 1 | |||||||||||
|
|||||||||||